What’s the best #CRM for a #nonprofit that already has its own website. (mailchimp, nationbuilder, everyaction, hubspot… etc)?
(Yes, It’s come to casting a question into the twittersea on a Sunday.)
Mailchimp seems like a fine mailing platform, but front end has overly simplistic forms (can’t seem to build in logic, like one can with surveymonkey or google forms) so can’t ask all questions we want to of new volunteers.
Nationbuilder seems built for non-profits, but they seem to want everyone to be fully in their site, making it sound complex it you have your own site. (Even still, not sure if they have dynamic/logical forms).
Seems most non-profits want as many supporters as possible to raise money from them. Understandable. But we are looking for something that’s better at sophisticated volunteer management; not all people the same so need dynamic forms so people don’t see tons of irrelevant fields.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
One might wonder if there was moment when Congress tweaked policy to discourage antibiotic R&D.
We are witnessing that moment again… as not single Dem Senator has spine to avert same thing happening to small molecule R&D for diseases of aging (cancer, Alz, Parkinson’s, etc). 
It’s demoralizing to see 50 powerful senators, each able to insist on simple budget-neutral fix, stay in herd.
They will demand applause for their leadership… but know, if they let this 9 vs 13 error stay in bill, they stood for nothing. just waste.
Reasonable, modest, & budget-neutral. An easy way to fix drug pricing policy legislation (currently being debated in Congress) that would earn support of patients, doctors, investors, & whole innovation community.
There's no reason to treat small molecules differently than biologics - but current bill's price negotiation sets in at only 9 years for small mols, while biologics get 13 years. That's four fewer years for a small molecule to generate a return. (2/x)
Certainly, Congress is busy, and there's a lot going on in the reconciliation bill that's worthwhile.
But this is one small fix that would avoid a monumental snafu. (3/x)
Lots of small dev-stage biotech companies use ATMs (or will) to raise money. Most have no idea how low fees could really be… answer: way lower than u know (<<2.25%).
Email me (CEO/CFOs have my email) to know which bank offers best rate as of this moment.
Save $’s for trials.
This will no doubt upset a few who currently enjoy the status quo. But times are tough for everyone. Senate bill threatens to kill small molecule drugs for diseases of aging. Cost of capital is high in public markets & higher on private side. Companies searching for savings.
Banks provide useful service & we need them to compete like hell to offer those services more efficiently. ATMs are one service where savings can be found.
No one entitled to any dollars… gotta fight for every one.
Congress is on the verge of gutting cancer & Alzheimer’s R&D w/ a few careless lines in reconciliation bill b/c seemingly everyone is tired of trying to do the right thing & thinks no one will notice.
You’ll never want to contribute to a campaign after this reading this. 1/20
First Democrats tried to pass HR3, which would have imposed price controls on any medicine that patients really wanted. That was just plain stupid, but sadly many Democrats (& a growing number of “new” Republicans) believe innovation grows on trees.
Patients, NIH-funded academic researchers, small biotech company executives, and investors pushed back, explaining that R&D would be gutted. I was one of the authors of a letter to Congress signed by hundreds. Here: nopatientleftbehind.org/letters-to-was…
Offering “help”, @MorningstarInc is instead punching patients in the face by unquestioningly adopting a weak branch of economics that patients say is racist, devalues those w/ disabilities, & intentionally undervalues meds so insurance denies them.😬
1/15 morningstar.com/articles/10994…
What @MorningstarInc is doing is so messed up, literally devaluing the lives of anyone with a disability, that Oklahoma banned it thanks to efforts of @AAPD & many other advocates for those w/disabilities. nationalreview.com/corner/oklahom…
So now @MorningstarInc is promoting ICER's math, which ignores that drugs go generic, offer risk reduction, spare caregivers, & lots more... condemning companies that invent medicines. Morningstar, you know math too well to fall for ICER's. I'll show you. morningstar.com/articles/10994…
This is the very same math that Austalia used to deny patients access to Vertex's Trikafta. Patient advocate @G17Esiason pointed out the flaws... scathingly. Australia changed its mind soon after. Gunnar can address you, too. realclearhealth.com/articles/2022/…
If your minds are still open, @MorningstarInc, please consider listening to this presentation that quantify ICER's errors. Once you take just a few missing variables into account, Trikafta goes from being "not worth it" to "well worth it".